Table 1 Demographic and clinical characteristics of the two patient groups
Variables | Group A | Group B | p-value |
|---|---|---|---|
3D-HDR-BT (n =118) | 2D-HDR-BT (n =101) | ||
Age (years) | 0.594 | ||
≤ 45 | 65 (11.9%) | 52 (20.8%) | |
> 45 | 53 (88.1%) | 49 (79.2%) | |
Mean | 44.6 | 47.1 | |
Median | 43 | 45 | |
Range | 19 - 80 | 18 - 73 | |
Gender | 0.100 | ||
Male | 88 (74.6%) | 65 (64.4%) | |
Female | 30 (25.4%) | 36 (35.6%) | |
Histology | 0.529 | ||
WHO type I/II | 2 (1.7%) | 3 (3.0%) | |
WHO type III | 116 (98.3%) | 98 (97.0%) | |
T-stage | 0.079 | ||
T1 | 65 (55.1%) | 42 (41.6%) | |
T2a | 34 (28.8%) | 41 (40.6%) | |
T2b | 19 (16.1%) | 18 (17.8%) | |
N-stage | 0.740 | ||
N0-1 | 85 (72.0%) | 74 (73.3%) | |
N2-3 | 33 (28.0%) | 27 (26.7%) | |
Chemotherapy | 0.740 | ||
Given | 33 (28.0%) | 27 (26.7%) | |
Not given | 85 (72.0%) | 74 (73.3%) | |
EBRT modality | |||
2D-CRT | 96 (81.4%) | 88 (87.1%) | 0.662 |
3D-CRT | 19 (16.1%) | 13 (12.9%) | |
IMRT | 3 (2.5%) | 0 (0%) |